U.S. markets close in 3 hours 9 minutes
  • S&P 500

    3,632.27
    +54.68 (+1.53%)
     
  • Dow 30

    30,068.97
    +477.70 (+1.61%)
     
  • Nasdaq

    12,013.91
    +133.28 (+1.12%)
     
  • Russell 2000

    1,857.07
    +38.78 (+2.13%)
     
  • Crude Oil

    44.99
    +1.93 (+4.48%)
     
  • Gold

    1,801.40
    -36.40 (-1.98%)
     
  • Silver

    23.25
    -0.39 (-1.64%)
     
  • EUR/USD

    1.1875
    +0.0030 (+0.25%)
     
  • 10-Yr Bond

    0.8850
    +0.0280 (+3.27%)
     
  • GBP/USD

    1.3340
    +0.0018 (+0.13%)
     
  • USD/JPY

    104.6340
    +0.1460 (+0.14%)
     
  • BTC-USD

    19,201.90
    +749.94 (+4.06%)
     
  • CMC Crypto 200

    381.10
    +11.35 (+3.07%)
     
  • FTSE 100

    6,432.17
    +98.33 (+1.55%)
     
  • Nikkei 225

    26,165.59
    +638.22 (+2.50%)
     

Will Infinity Pharmaceuticals Continue to Surge Higher?

Zacks Equity Research
Investors are looking forward to the performance of Salix and Bausch + Lomb, and other pipeline updates, when Bausch (BHC) reports Q1 results on May 6.
Investors are looking forward to the performance of Salix and Bausch + Lomb, and other pipeline updates, when Bausch (BHC) reports Q1 results on May 6.

 

As of late, it has definitely been a great time to be an investor in Infinity Pharmaceuticals, Inc. INFI. The stock has moved higher by 25.7% in the past month, while it is also above its 20 Day SMA too. This combination of strong price performance and favorable technical, could suggest that the stock may be on the right path.

We certainly think that this might be the case, particularly if you consider INFI’s recent earnings estimate revision activity. From this look, the company’s future is quite favorable; as INFI has earned itself a Zacks Rank #2 (Buy), meaning that its recent run may continue for a bit longer, and that this isn’t the top for the in-focus company. You can see the complete list of today’s Zacks #1 Rank stocks here.

Zacks' Top 10 Stocks for 2019

In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-holds for the year?

Who wouldn't? Our annual Top 10s have beaten the market with amazing regularity. In 2018, while the market dropped -5.2%, the portfolio scored well into double-digits overall with individual stocks rising as high as +61.5%. And from 2012-2017, while the market boomed +126.3, Zacks' Top 10s reached an even more sensational +181.9%.

See Latest Stocks Today >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Infinity Pharmaceuticals, Inc. (INFI) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research